These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 17667001)

  • 1. Preventing respiratory syncytial virus in homebound premature infants.
    Austin J
    Home Healthc Nurse; 2007; 25(7):429-32. PubMed ID: 17667001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decline in respiratory syncytial virus hospitalizations in a region with high hospitalization rates and prolonged season.
    Singleton RJ; Bruden D; Bulkow LR; Varney G; Butler JC
    Pediatr Infect Dis J; 2006 Dec; 25(12):1116-22. PubMed ID: 17133156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RSV: protecting the littlest patients.
    Lauts NM
    RN; 2005 Dec; 68(12):46-51; quiz 52. PubMed ID: 16411554
    [No Abstract]   [Full Text] [Related]  

  • 4. Preventing RSV bronchiolitis in vulnerable infants: the role of palivizumab.
    Fitzgerald DA
    Paediatr Respir Rev; 2009 Sep; 10(3):143-7. PubMed ID: 19651385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of palivizumab monoclonal antibody to control an outbreak of respiratory syncytial virus infection in a special care baby unit.
    Cox RA; Rao P; Brandon-Cox C
    J Hosp Infect; 2001 Jul; 48(3):186-92. PubMed ID: 11439005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved outcomes with home-based administration of palivizumab: results from the 2000-2004 Palivizumab Outcomes Registry.
    Frogel M; Nerwen C; Boron M; Cohen A; VanVeldhuisen P; Harrington M; Groothuis J;
    Pediatr Infect Dis J; 2008 Oct; 27(10):870-3. PubMed ID: 18776822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strategies for prevention of RSV nosocomial infection.
    Groothuis J; Bauman J; Malinoski F; Eggleston M
    J Perinatol; 2008 May; 28(5):319-23. PubMed ID: 18368056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prophylaxis against respiratory syncytial virus in high-risk infants: administration of immune globulin and epidemiological surveillance of infection.
    Handal G; Logvinoff MM; Zegarra N; Allen L; Jesurun A; Levin G; Thida A
    Tex Med; 2000 May; 96(5):58-61. PubMed ID: 10843015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk-Scoring Tool for respiratory syncytial virus prophylaxis in premature infants born at 33-35 completed weeks' gestational age in Canada.
    Paes B; Steele S; Janes M; Pinelli J
    Curr Med Res Opin; 2009 Jul; 25(7):1585-91. PubMed ID: 19469698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of parental and household smoking on the risk of respiratory syncytial virus (RSV) hospitalisation in late-preterm infants and the potential impact of RSV prophylaxis.
    Carbonell-Estrany X; Fullarton JR; Gooch KL; Vo PG; Figueras-Aloy J; Lanari M; Gouyon JB; Liese JG
    J Matern Fetal Neonatal Med; 2013 Jun; 26(9):926-31. PubMed ID: 23379728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nurse role in RSV management.
    Whelan B
    Early Hum Dev; 2012 May; 88 Suppl 2():S29-30. PubMed ID: 22633508
    [No Abstract]   [Full Text] [Related]  

  • 12. Respiratory syncytial virus (RSV) loads in premature infants with and without prophylactic RSV fusion protein monoclonal antibody.
    DeVincenzo JP; Aitken J; Harrison L
    J Pediatr; 2003 Jul; 143(1):123-6. PubMed ID: 12915838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Appropriate prophylaxis with restrictive palivizumab regimen in preterm children in Sweden.
    Navér L; Eriksson M; Ewald U; Linde A; Lindroth M; Schollin J
    Acta Paediatr; 2004 Nov; 93(11):1470-3. PubMed ID: 15513574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FLIP-2 Study: risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born in Spain at a gestational age of 32 to 35 weeks.
    Figueras-Aloy J; Carbonell-Estrany X; Quero-Jiménez J; Fernández-Colomer B; Guzmán-Cabañas J; Echaniz-Urcelay I; Doménech-Martínez E;
    Pediatr Infect Dis J; 2008 Sep; 27(9):788-93. PubMed ID: 18664927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experience with the use of palivizumab together with infection control measures to prevent respiratory syncytial virus outbreaks in neonatal intensive care units.
    Kurz H; Herbich K; Janata O; Sterniste W; Bauer K
    J Hosp Infect; 2008 Nov; 70(3):246-52. PubMed ID: 18799241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry.
    Frogel M; Nerwen C; Cohen A; VanVeldhuisen P; Harrington M; Boron M;
    J Perinatol; 2008 Jul; 28(7):511-7. PubMed ID: 18368063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population based external validation of a European predictive model for respiratory syncytial virus hospitalization of premature infants born 33 to 35 weeks of gestational age.
    Stensballe LG; Fullarton JR; Carbonell-Estrany X; Simões EA
    Pediatr Infect Dis J; 2010 Apr; 29(4):374-6. PubMed ID: 20016397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Respiratory syncytial virus season and hospitalizations in the Alaskan Yukon-Kuskokwim Delta.
    Singleton RJ; Bruden D; Bulkow LR
    Pediatr Infect Dis J; 2007 Nov; 26(11 Suppl):S46-50. PubMed ID: 18090200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beyond randomized controlled trials: a "real life" experience of respiratory syncytial virus infection prevention in infancy with and without palivizumab.
    Mitchell I; Tough S; Gillis L; Majaesic C
    Pediatr Pulmonol; 2006 Dec; 41(12):1167-74. PubMed ID: 17058279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health plan pharmacy director: considerations for treatment and management of RSV disease.
    Burgoyne DS
    Manag Care; 2008 Nov; 17(11 Suppl 12):17-8, discussion 18-9. PubMed ID: 19102025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.